Elix and University of Vienna Enter Joint Research Agreement for AI Drug Discovery

Japanese AI drug discovery company Elix is partnering with the University of Vienna to combine its AI molecular generation platform with the university's advanced NMR spectroscopy. The collaboration will focus on designing novel compounds for 'undruggable' targets in areas like cancer and epigenetic signaling.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.